<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154737">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01922791</url>
  </required_header>
  <id_info>
    <org_study_id>T166/2012</org_study_id>
    <nct_id>NCT01922791</nct_id>
  </id_info>
  <brief_title>Nutrition and Pregnancy Intervention Study</brief_title>
  <official_title>Placebo-controlled Intervention Study for Maternal and Child Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Turku</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <authority>Finland: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized double-blind placebo controlled intervention study with pregnant obese women
      (n=440) will be conducted. The intervention will involve consumption of fish oil and/or
      probiotic capsules from early pregnancy until 6 months after delivery.

      The aim of the study is firstly to investigate the effects of the supplements on the risk of
      gestational diabetes mellitus and obesity in the women and secondly to modify the risk
      markers of allergy and obesity in children of the women. Also the underlying metabolic
      mechanisms will be investigated.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Prevalence of gestational diabetes mellitus, GDM</measure>
    <time_frame>Assessed at gestational weeks 24-28</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting glucose levels</measure>
    <time_frame>assessed at the third trimester of pregnancy</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of allergy in child</measure>
    <time_frame>assessed at 12 and 24 months of age</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need for medication for management of gestational diabetes mellitus GDM (insulin or metformin)</measure>
    <time_frame>During pregnancy</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition of mother</measure>
    <time_frame>During and after pregnancy</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunologic and metabolic markers</measure>
    <time_frame>During and after pregnancy</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal microbiota</measure>
    <time_frame>Before, during and after intervention</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Body composition, growth, development and metabolic markers of the child</measure>
    <time_frame>0 to 24 months of age</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Pregnancy</condition>
  <condition>Obesity</condition>
  <condition>Gestational Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Comparison of probiotics, fish oil and their combination to placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fish oil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Comparison of probiotics, fish oil and their combination to placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotics and Fish oil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Comparison of probiotics, fish oil and their combination to placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Comparison of probiotics, fish oil and their combination to placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Comparison of probiotics, fish oil and their combination to placebo</intervention_name>
    <description>Double-blind randomized placebo controlled intervention</description>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_label>Fish oil</arm_group_label>
    <arm_group_label>Probiotics and Fish oil</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Lactobacillus and Bifidobacterium</other_name>
    <other_name>Fish oil</other_name>
    <other_name>Placebo, microcrystalline cellulose</other_name>
    <other_name>Placebo, medium-chain triglycerides</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pregnant, less than 16 gestational weeks

          -  overweight

          -  healthy

        Exclusion Criteria:

          -  Diabetes (type 1 or 2)

          -  Coeliac disease

          -  Increased bleeding tendency
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kirsi Laitinen, PhD, docent</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Turku</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kirsi Laitinen, Adjunct professor</last_name>
    <phone>+ 358 02 333 6063</phone>
    <email>kirsi.laitinen@utu.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Henna Röytiö, PhD</last_name>
    <phone>+358 02 333 6865</phone>
    <email>henna.roytio@utu.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Outi Pellonperä, MD</last_name>
      <email>outi.pellonpera@tyks.fi</email>
    </contact>
    <investigator>
      <last_name>Ulla Ekblad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Outi Pellonperä, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Turku</name>
      <address>
        <city>Turku</city>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henna Röytiö, PhD</last_name>
      <phone>+358 2 333 6865</phone>
      <email>henna.roytio@utu.fi</email>
    </contact>
    <investigator>
      <last_name>Kirsi Laitinen, PhD, adjunct professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henna Röytiö, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <link>
    <url>http://www.utu.fi</url>
    <description>University of Turku</description>
  </link>
  <link>
    <url>http://www.tyks.fi</url>
    <description>Turku University Hospital</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>August 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Turku</investigator_affiliation>
    <investigator_full_name>Kirsi Laitinen</investigator_full_name>
    <investigator_title>Adjunct professor</investigator_title>
  </responsible_party>
  <keyword>Nutrition</keyword>
  <keyword>Probiotics</keyword>
  <keyword>Fish oil</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Diabetes, Gestational</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
